Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:APRE NYSEAMERICAN:AZTR OTCMKTS:GLUC NASDAQ:RNAZ On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPREAprea Therapeutics$0.67-0.4%$0.79$0.55▼$2.22$8.25M1.51.13 million shs162 shsAZTRAzitra$0.14-3.4%$0.19$0.10▼$1.60$2.28M-1.2111.01 million shs130,400 shsGLUCGlucose Health$0.32$0.41$0.02▼$0.67$8.60M13,975 shs2,347 shsRNAZTransCode Therapeutics$8.43-3.4%$6.38$3.82▼$20.99$8.01M1.23140,266 shs5,550 shs7 Stocks That Could Lead the Next Market BoomTesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPREAprea Therapeutics-1.62%-7.34%-6.43%-26.26%-59.70%AZTRAzitra+5.04%+12.22%-14.97%-30.48%-90.34%GLUCGlucose Health0.00%-13.51%-38.10%-13.51%+228.21%RNAZTransCode Therapeutics+3.56%+1.99%+85.74%+2.83%-12.17%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPREAprea Therapeutics$0.67-0.4%$0.79$0.55▼$2.22$8.25M1.51.13 million shs162 shsAZTRAzitra$0.14-3.4%$0.19$0.10▼$1.60$2.28M-1.2111.01 million shs130,400 shsGLUCGlucose Health$0.32$0.41$0.02▼$0.67$8.60M13,975 shs2,347 shsRNAZTransCode Therapeutics$8.43-3.4%$6.38$3.82▼$20.99$8.01M1.23140,266 shs5,550 shs7 Stocks That Could Lead the Next Market BoomTesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPREAprea Therapeutics-1.62%-7.34%-6.43%-26.26%-59.70%AZTRAzitra+5.04%+12.22%-14.97%-30.48%-90.34%GLUCGlucose Health0.00%-13.51%-38.10%-13.51%+228.21%RNAZTransCode Therapeutics+3.56%+1.99%+85.74%+2.83%-12.17%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAPREAprea Therapeutics 2.40Hold$4.07510.61% UpsideAZTRAzitra 3.00Buy$4.002,736.88% UpsideGLUCGlucose Health 0.00N/AN/AN/ARNAZTransCode Therapeutics 1.00SellN/AN/ACurrent Analyst Ratings BreakdownLatest AZTR, GLUC, APRE, and RNAZ Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/17/2026APREAprea Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)7/17/2026RNAZTransCode Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)5/14/2026APREAprea Therapeutics WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$7.00 ➝ $6.005/7/2026APREAprea Therapeutics OppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$5.004/21/2026RNAZTransCode Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)(Data available from 7/21/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAPREAprea Therapeutics$290K28.43N/AN/A$1.52 per share0.44AZTRAzitra$10K228.28N/AN/A$0.35 per share0.40GLUCGlucose Health$340K25.30N/AN/AN/A∞RNAZTransCode TherapeuticsN/AN/AN/AN/A$11.27 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAPREAprea Therapeutics-$12.60M-$1.54N/AN/AN/A-4,405.59%-61.03%-50.24%8/11/2026 (Estimated)AZTRAzitra-$10.95MN/AN/AN/AN/AN/A-251.51%-185.99%8/10/2026 (Estimated)GLUCGlucose Health-$230K-$0.03N/AN/AN/A-84.68%N/AN/AN/ARNAZTransCode Therapeutics-$34.66M-$50.33N/AN/AN/AN/A-875.35%-50.36%8/18/2026 (Estimated)Latest AZTR, GLUC, APRE, and RNAZ EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/11/2026Q2 2026APREAprea Therapeutics-$0.23N/AN/AN/A$0.25 millionN/A8/10/2026Q2 2026AZTRAzitra-$0.1150N/AN/AN/AN/AN/A5/15/2026Q1 2026GLUCGlucose HealthN/A-$0.01N/A-$0.01N/A$0.06 million5/15/2026Q1 2026RNAZTransCode TherapeuticsN/A-$21.28N/A-$21.28N/AN/A5/13/2026Q1 2026APREAprea Therapeutics-$0.23-$0.22+$0.01-$0.22$0.00 millionN/A5/13/2026Q1 2026AZTRAzitra-$0.01-$0.25-$0.24-$0.25N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAPREAprea TherapeuticsN/AN/AN/AN/AN/AAZTRAzitraN/AN/AN/AN/AN/AGLUCGlucose HealthN/AN/AN/AN/AN/ARNAZTransCode TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAPREAprea TherapeuticsN/A8.928.92AZTRAzitraN/A6.946.94GLUCGlucose HealthN/AN/AN/ARNAZTransCode TherapeuticsN/A3.113.11Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAPREAprea Therapeutics34.19%AZTRAzitra11.16%GLUCGlucose HealthN/ARNAZTransCode TherapeuticsN/AInsider OwnershipCompanyInsider OwnershipAPREAprea Therapeutics10.49%AZTRAzitra0.28%GLUCGlucose HealthN/ARNAZTransCode Therapeutics0.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAPREAprea Therapeutics712.38 million11.08 millionNo DataAZTRAzitra1016.19 million16.15 millionNot OptionableGLUCGlucose Health147,00026.88 millionN/ANot OptionableRNAZTransCode Therapeutics9950,000949,000Not OptionableAZTR, GLUC, APRE, and RNAZ HeadlinesRecent News About These CompaniesTransCode Therapeutics Stockholders Approve Share Issuance Plans, Board SlateJuly 21 at 4:05 AM | americanbankingnews.comTransCode Therapeutics Inc RNAZJuly 3, 2026 | morningstar.comMTransCode Therapeutics, Inc. (RNAZ) Discusses Strategic, Scientific, and Clinical Updates With Focus on TTX-MC138 Phase 2a Trial in Colorectal Cancer Prepared Remarks TranscriptJune 18, 2026 | seekingalpha.comRNAZ: Introducing RNA therapeuticsJune 8, 2026 | msn.comTransCode Therapeutics to Host R&D Webcast on June 18, 2026June 8, 2026 | prnewswire.comRNAZ Share News TodayJune 4, 2026 | uk.investing.comEXCLUSIVE: TransCode's RNA Therapeutic Achieves 64% Stable Disease Rate In Colorectal Cancer Phase 1 StudyJune 3, 2026 | finance.yahoo.comTransCode Therapeutics Successfully Completes Phase 1a Clinical Trial, Reports Safety and Stabilization Data for TTX-MC138 in Metastatic CancerJune 3, 2026 | prnewswire.comTransCode Therapeutics, Inc.: TransCode Therapeutics Initiates Phase 2a Clinical Trial with TTX-MC138 in Patients with ctDNA Positive Colorectal CancerMay 28, 2026 | finanznachrichten.deTransCode Therapeutics Initiates Phase 2a Clinical Trial with TTX-MC138 in Patients with ctDNA Positive Colorectal CancerMay 27, 2026 | prnewswire.comTransCode Therapeutics Appoints Dr. Anna Moore as Chair of Scientific Advisory Board; Announces Sponsored Research Agreement with Michigan State UniversityApril 27, 2026 | prnewswire.comTransCode Therapeutics signs financing deal worth up to $20 millionApril 8, 2026 | msn.comTransCode Therapeutics Enters into Agreements for up to $20 Million Flexible Financing, Extending Company's Runway into Late 2027/Early 2028April 7, 2026 | prnewswire.comTransCode Secures Exclusive, Worldwide, Fully Paid-Up Royalty-Free License to Develop and Commercialize a Next-Generation Oncolytic Immunotherapy Platform in an All-Stock Transaction Underscoring the Company's Dedication to Improving the Lives of Cancer PatientsMarch 3, 2026 | prnewswire.comTransCode Therapeutics Announces Publication of Preclinical Testing of RIG-I Immunotherapeutic Candidate Supporting Further DevelopmentFebruary 23, 2026 | prnewswire.comTransCode Therapeutics Advances Phase 2a Colorectal Cancer TrialFebruary 11, 2026 | theglobeandmail.comTransCode Therapeutics, Inc.: TransCode Therapeutics and Quantum Leap Announce Submission of IND Amendment for Phase 2a Clinical Trial with TTX-MC138February 5, 2026 | finanznachrichten.deTransCode Therapeutics and Quantum Leap Announce Submission of IND Amendment for Phase 2a Clinical Trial with TTX-MC138February 5, 2026 | prnewswire.comTransCode Therapeutics reports promising preclinical glioblastoma resultsJanuary 6, 2026 | msn.comTransCode Therapeutics stock soars after promising glioblastoma studyJanuary 6, 2026 | uk.investing.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeAZTR, GLUC, APRE, and RNAZ Company DescriptionsAprea Therapeutics NASDAQ:APRE$0.67 0.00 (-0.45%) As of 09:44 AM Eastern This is a fair market value price provided by Massive. Learn more.Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors. The company is also developing ATRN-1051 for the treatment of ovarian cancer; and APRE-DDRi for the treatment of advanced solid tumors. The company is headquartered in Doylestown, Pennsylvania.Azitra NYSEAMERICAN:AZTR$0.14 -0.01 (-3.42%) As of 10:05 AM Eastern This is a fair market value price provided by Massive. Learn more.Azitra, Inc., an early-stage biopharmaceutical company, develops therapies for precision dermatology using engineered proteins and live biotherapeutic products to treat skin diseases. It develops ATR-12, a genetically modified strain of S. epidermidis, which is in Phase Ib clinical trial for treating Netherton syndrome, a skin disease. The company also develops ATR-04, a genetically modified strain of S. epidermidis for treating the papulopustular rash experienced by cancer patients undergoing epidermal growth factor receptor inhibitor; and ATR-01, an engineered recombinant human filaggrin protein for treating ichthyosis vulgaris, a skin disease. It has a collaboration with Bayer. The company was incorporated in 2014 and is based in Branford, Connecticut.Glucose Health OTCMKTS:GLUC$0.32 0.00 (0.00%) As of 07/17/2026 10:42 AM EasternGlucose Health, Inc. engages in the formulation, manufacturing, marketing, and distribution of soluble fiber infused nutritional beverages. It offers soluble fiber infused powdered iced tea, and flavored drink mixes for pre-diabetic and diabetic persons under the GLUCODOWN brand in North America. The company was formerly known as Bio-Solutions Corp. and changed its name to Glucose Health, Inc. in November 2014. Glucose Health, Inc. was incorporated in 2007 and is based in Bentonville, Arkansas.TransCode Therapeutics NASDAQ:RNAZ$8.43 -0.30 (-3.44%) As of 10:04 AM Eastern This is a fair market value price provided by Massive. Learn more.TransCode Therapeutics, Inc., a ribonucleic acid (RNA) oncology company, focuses on the development and commercialization of drugs and diagnostics for treating and identifying various cancers. Its lead therapeutic candidate is TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in a range of cancers, including breast, pancreatic, ovarian, colon cancer, glioblastomas, and others. The company is also developing TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1; and TTX-siLIN28B, an siRNA-based inhibitor of RNA-binding protein LIN28B. In addition, the company developing TTX-RIGA, an RNA- based agonist of the retinoic acid-inducible gene I targeting activation of innate immunity in the tumor microenvironment; TTX-CRISPR, a CRISPR/Cas9-based therapy platform for the repair or elimination of cancer-causing genes inside tumor cells; and TTX-mRNA, an mRNA-based platform for the development of cancer vaccines that activate cytotoxic immune responses against tumor cells. TransCode Therapeutics, Inc. was incorporated in 2016 and is based in Boston, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Buy, Hold, or Wait: 3 Small-Cap Stocks Telling Different Stories The Ugliest Stocks in the Market Just Got a Very Expensive Vote of Confidence Is Domino's Stock Serving Up a Buying Opportunity? IBM Just Had Its Worst Day Ever—What Earnings Must Prove AI Data Centers Need Power, and These 2 Industrials Are Cashing In 5 Stocks Quietly Trading Near All-Time Highs While Everyone Watches the AI Drama Meta Platforms Turns AI Power Scarcity Into a $10 Billion Cloud Bet Oracle Is One Step From Junk—Can It Afford the AI Boom? Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
